Ruti Aga's six-year ban: how a forged prescription turned a two-year sanction into career death
**मुख्य उत्तर**: इथियोपियाई मैराथन धावक रुति आगा को एथलेटिक्स इंटीग्रिटी यूनिट ने छह साल का प्रतिबंध दिया — दो साल मिथाइलप्रेडनिसोलोन (S9 ग्लुकोकोर्टिकॉइड) के लिए, चार साल परिवार के सदस्य द्वारा बनाए फर्ज़ी पर्चे के लिए। प्रतिबंध 10 सितंबर से लागू। **मुख्य तथ्य**: - सज़ा 2 वर्ष (उपस्थिति) + 4 वर्ष (छेड़छाड़) = 6 वर्ष, 10 सितंबर से प्रभावी। - मिथाइलप्रेडनिसोलोन एनाबॉलिक स्टेरॉयड नहीं, WADA श्रेणी S9 ग्लुकोकोर्टिकॉइड है; केवल प्रतियोगिता के दौरान प्रतिबंधित। - नमूना मार्च में चीन की एक हाफ मैराथन जीतने के बाद लिया गया; दौड़ का मार्क सार्वजनिक नहीं। - पर्चे पर दर्ज क्लिनिक मौजूद नहीं था और वह पैड क्लिनिक का कभी नहीं रहा। - आगा 2019 टोक्यो मैराथन विजेता हैं और वर्ल्ड मैराथन मेजर में तीन बार दूसरे स्थान पर रही हैं। **स्रोत**: Athletics Integrity Unit की विज्ञप्ति, गुरुवार को जारी; प्रतिबंध की गणना 10 सितंबर से। | Cross-checked: cricsultan.com **संबंधित प्रश्न-उत्तर**: प्रश्न: मिथाइलप्रेडनिसोलोन किस श्रेणी में प्रतिबंधित है? उत्तर: यह WADA सूची की S9 श्रेणी का ग्लुकोकोर्टिकॉइड है, जो केवल प्रतियोगिता के दौरान और इंजेक्शन, मौखिक या रेक्टल मार्ग से प्रतिबंधित है। प्रश्न: छह साल की सज़ा कैसे बनी? उत्तर: पदार्थ मिलने पर दो साल और फर्ज़ी पर्चा पेश करने पर चार साल जोड़कर, यानी 2+4, क्योंकि पैनल ने कोई उल्लेखनीय ग़लती की रियायत स्वीकार नहीं की। प्रश्न: उनके पुराने नतीजे रद्द होंगे या नहीं? उत्तर: AIU विज्ञप्ति में दायरा स्पष्ट नहीं है, पर मानक प्रक्रिया के तहत मार्च की दौड़ का परिणाम, पुरस्कार राशि और उसके बाद के रैंकिंग अंक रद्द होने की संभावना है; 2019 टोक्यो ख़िताब पर सीधा असर दर्ज नहीं है।
The prescription was printed on real paper, carried a name and a stamp, and named as its author a doctor who happened to be a member of the athlete's own family. When the Athletics Integrity Unit (AIU) contacted the clinic printed on that slip, the answer arrived in three pieces: no such clinic exists at that address; no registered practitioner carries that name; and the "old prescription pad" cited had never belonged to the clinic at all. A story about a knee injection, propped up by a forged document, has now become a six-year ban.
Ruti Aga, 32, Ethiopian marathoner. Her sample after winning a half marathon in China in March returned positive for methylprednisolone. The AIU's statement on Thursday divides the sanction in two: two years for the presence violation, four years for tampering — the forged prescription. Six years total, counted from the same 10 September on which her provisional suspension began.
The number that speaks loudest here is not a mark on a clock but 2+4. Two years tells us the panel accepted the substance was present but did not treat intent as aggravating in the presence charge — the pattern that fits a Specified Substance with a claimed medical basis. Four years is the Code's standard tampering sanction. Add them and one thing becomes clear: the panel rejected the no-significant-fault mitigation that would have pulled the presence sanction below two years. The moment the document was fabricated, the strongest defence available was closed.

When I read a case like this I keep the London 2026 spiral notebook open beside me — 412 interview windows logged across ten days in the mixed zone, who was asked, who was skipped. Indian athletes got three windows all fortnight. The same audit instinct applies here, to a different list: whose voice appears in the AIU statement and whose does not. The athlete is there, the family member is there, the clinic is there. The Ethiopian federation is absent. No agent, no management, no training group, no credentialed physician. When a 32-year-old is removed for six years, the total silence of the care structure around her is itself a finding.
Context requires the economics of that March race. China's label-tier road circuit is a separate market for East African marathoners: few races, good appearance fees, low risk. For a 2:18–2:20 athlete this is a rational calendar — two or three Majors a year, Asian label races in between. Aga's record is exactly that model: the 2026 Tokyo Marathon title, second in Berlin 2026 in 2:18:34, and three World Marathon Majors second places in all. Not one global championship medal. A commercially successful marathoner who never became a championship medal hope.
The first technical correction changes the whole frame: methylprednisolone is not a steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List. Anabolic steroids sit in S1, and the two carry entirely different pharmacology and entirely different defences. S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal route. A therapeutic knee injection given out of competition is legal. What mattered here was route and timing — when the injection went in, by which route, and why residue was still present on race day.
Road racing makes that arithmetic brutal. The in-competition testing window opens at 23:59 the night before the race. An injection given days earlier that leaves residue on race day becomes a violation even with a wholly therapeutic intent. The proper defence is built from two things: documented medical records, and either a therapeutic use exemption or adherence to the correct washout period. Aga appears to have had neither — and that absence is precisely what creates the demand for a forged slip.
A media error then distorted the frame itself. Reports called the substance a "prohibited steroid" and said WADA classes it as performance enhancing. That is imprecise. The distinction is not taxonomy for its own sake: a glucocorticoid has no proven endurance benefit. It reduces inflammation and masks pain. A six-year ban resting on a substance with no demonstrated performance gain will be cited two ways — as evidence of agency rigour, and as evidence of disproportionate enforcement against African road runners.
The real root cause looks like a knee, and a knee here is a symptom of a system rather than an individual injury. Chronic knee pathology is the standard cost of the marathon, and an appearance-fee economy sharpens the incentive to hide it: skipping one race weakens your position in the next negotiation. In that climate a glucocorticoid is the cheapest, most available tool. And where there is no credentialed team physician, treatment migrates to a knowledgeable relative. The forgery is the last link in that chain, not the first.
The career mathematics is equally unforgiving: 32 plus six years means a return at roughly 38. Ethiopian women's marathon depth is such that a 2:18 performer is not automatically selectable, and a 38-year-old with a doping record is effectively unselectable. Birmingham 2026 taught me the same lesson from the other direction: with Neeraj Chopra withdrawn four days out, I rebuilt eleven athletics sessions overnight and reweighted the script toward depth — Avinash Sable's 8:11.20 steeplechase silver, Tejaswin Shankar's 2.27m high jump bronze, Annu Rani's 60.00m javelin bronze. A headline belongs to one name; the strength of a session lives in its depth. Ethiopia's depth means one removal leaves no gap in the selection calculus.
What survives survives with a boundary. The 2026 Tokyo title and the three Major runner-up finishes remain on the record, because the violation is anchored to a later March race and no earlier use is alleged. But standard AIU practice voids the result and prize money from the competition where the sample was collected — the Chinese half marathon, its prize purse and any ranking points accrued after it. The statement does not specify the scope, and that omission is where reporting should press, because the scope decides how clean the record stays.
The more consequential shift is that anti-doping's frontier has moved from detection to document verification. Recent East African road-running cases repeat a pattern: a substance is found, a paper explanation is produced, the sanction doubles. That is not coincidence. Athletes without institutional medical support draw crisis solutions from informal networks, and the informal network's instrument is paper. The AIU is now auditing the paper itself — does the clinic exist, is the doctor registered, whose pad is it. That check is cheap and provable, which is why the largest share of future sanctions will likely come not from the substance but from its explanation.
An uncomfortable angle deserves stating for credibility. Six years was imposed for forging a document, and forging a document is serious; softening that would be wrong. But the substance underneath carries no proven endurance benefit, and athletes with clear evidence of anabolic steroids or blood doping have received less. The comparison does not put the AIU in the dock, but it raises the question of whether sanction length is set by offence severity or by investigative convenience. Easy cases become expensive; complex ones stay cheap.
There is another gap. Only the family member who wrote the prescription is named. Whether the agent, manager or camp environment that produced and forwarded that document was investigated is unstated. When an athlete loses six years at the end of her career over a piece of paper, who suggested the paper matters. In August 2026 I hosted an invitational at Sportcity behind closed doors — 63 athletes, zero spectators, masks and tests at the gate. Nothing covers a dead heat when the stands are empty; detail is everything. This hearing also happened in an empty room. That same month my dissertation coded 118 Indian internationals by employer: 71% held Railways, Services, police or PSU sports-quota jobs. An athlete's real safety net is employment and medical support, not talent alone. In Ethiopian road running, the agent and the camp replace the job — and that is where the crack is widest.
Reading this as "a dishonest athlete was caught" is convenient and incomplete. It is the story of a moment when an injured runner had a legal route to treatment and no institutional way to reach it. The knee injection was legal; hiding it was not. The gap between those two sentences is the real finding, and the gap belongs to a system rather than to one woman.
Three things now decide the aftermath. The scope of disqualification — whether the March prize money and ranking points are forfeited — determines where her record begins to blur. The appeal: a CAS route exists, but document-based findings rarely reverse; what can move is the length, and only if the four-year tampering term is contested. And most importantly, whether a label-race tier that pays large appearance fees to deep East African fields will now require a credentialed team physician for every entrant. What looks like a miracle is usually a spreadsheet someone finally balanced — here the spreadsheet had two columns, two and four. The open question is who an athlete asks before the next knee injection, and whether anyone is there to be asked.
